 |
|
|
| |
Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in
patients with genotype 1 HCV: Real-world experience from the TRIO Network.
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23
N. Tsai1, B. Bacon2, M. Curry3, D. Dieterich4, S.L. Flamm5, K. Kowdley6, S. Milligan7, Z. Younossi8 and N. Afdhal3
1Queens Medical Center, University of Hawaii, 2Saint Louis University School of Medicine, 3Beth Israel Deaconess Medical Center, 4Icahn School of Medicine at Mount Sinai, 5Northwestern University Feinberg School of Medicine, 6Liver Care Network, Swedish Medical Center, 7Trio Health Analytics, and 8Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital
|
| |
|
|
|
|
|
